Clinical trial
A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma…
NCT00401596 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00401596 |
|---|---|
| Title | A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO) |
| Official title | A Multicenter, Randomized, Controlled, Open-Label Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Subjects Already Treated With Other Therapies (ALTO) |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Xolair (omalizumab) |
| Enrollment | 1,899 |
| Start date | Jul 1, 2000 |
| Completion | Jul 1, 2002 |
| First posted | Nov 20, 2006 |
| Last update posted | Mar 19, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: